Editorial Comment to Real‐World Occurrence of Adverse Events Associated With Adjuvant Pembrolizumab Therapy for Renal Cell Carcinoma: A Multicenter Retrospective Study
International Journal of Urology · 2026-06 · 33 (6)
DOI: 10.1111/iju.70545 ↗Kurz gefasst
Editorial in der Zeitschrift International Journal of Urology, online erschienen am 19.06.2026. Verfasst von Hajime Tanaka. Beteiligte Einrichtung: Department of Urology, Institute of Science Tokyo, Tokyo, Japan. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 5 Literaturangaben.
Themen: Patientensicherheit
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Department of Urology, Institute of Science Tokyo, Tokyo, Japan.
ORCID-Profile: Hajime Tanaka
Zitieren
APA
Tanaka, H. (2026). Editorial Comment to Real‐World Occurrence of Adverse Events Associated With Adjuvant Pembrolizumab Therapy for Renal Cell Carcinoma: A Multicenter Retrospective Study. International Journal of Urology, 33(6). https://doi.org/10.1111/iju.70545
Vancouver
Tanaka H. Editorial Comment to Real‐World Occurrence of Adverse Events Associated With Adjuvant Pembrolizumab Therapy for Renal Cell Carcinoma: A Multicenter Retrospective Study. International Journal of Urology. 2026;33(6). doi:10.1111/iju.70545
BibTeX
@article{Tanaka2026,
author = {Tanaka, Hajime},
title = {Editorial Comment to Real‐World Occurrence of Adverse Events Associated With Adjuvant Pembrolizumab Therapy for Renal Cell Carcinoma: A Multicenter Retrospective Study},
journal = {International Journal of Urology},
year = {2026},
volume = {33},
number = {6},
doi = {10.1111/iju.70545}
}
EUVIMED